A5085921508- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Organ Transplantation Techniques and Outcomes
- Hepatitis B Virus Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis Viruses Studies and Epidemiology
- Renal Transplantation Outcomes and Treatments
- Gastrointestinal disorders and treatments
- Pancreatic and Hepatic Oncology Research
- Tracheal and airway disorders
- Vascular Anomalies and Treatments
- HIV/AIDS drug development and treatment
- IgG4-Related and Inflammatory Diseases
- Liver Diseases and Immunity
- Pleural and Pulmonary Diseases
- Drug-Induced Hepatotoxicity and Protection
- Esophageal and GI Pathology
- Ultrasound in Clinical Applications
- Pericarditis and Cardiac Tamponade
- Electrolyte and hormonal disorders
- Gallbladder and Bile Duct Disorders
- Pancreatitis Pathology and Treatment
- Vascular Malformations and Hemangiomas
- Organ Donation and Transplantation
Mayo Clinic in Arizona
2014-2025
Mayo Clinic
2016-2025
WinnMed
2008-2023
Center for Neuroscience and Regenerative Medicine
2016
Advanced Imaging Research (United States)
2011
The evolution of metabolic and cardiovascular disease (CVD) complications after liver transplantation (LT) is poorly characterized. We aim to illustrate the prevalence obesity syndrome (MS), define cumulative incidence CVD, characterize risk factors associated with these comorbidities LT. A retrospective review 455 consecutive LT recipients from 1999 2004 an 8‐ 12‐year follow‐up was performed. Obesity increased 23.8% (4 months) 40.8% (3 years) Increase in body mass index predicted MS at 1...
Treatment with an all‐oral interferon‐free antiviral regimen using simeprevir and sofosbuvir or without ribavirin (RBV) for 12 weeks resulted in high sustained virologic response (SVR) rates along minimal adverse events non–liver transplant (LT) patients hepatitis C virus (HCV) genotype 1 infection. This is the first multicenter report on efficacy, safety, tolerability of this LT recipients. A total 123 (76% male, 74% white, 60% 1a, 30% METAVIR F3‐F4, 4% decompensation, 11% cholestatic...
Treatment options for refractory hepatic encephalopathy (HE) are limited. Patients who fail medical management may harbor large portosystemic shunts (PSSs) which possible therapeutic targets. This study aims to describe patient selection, effectiveness, and safety of percutaneous PSS embolization in those with medically HE. A retrospective evaluation consecutive adult patients HE referred at a tertiary center was performed (2003‐2015). Patient data collected included the type HE,...
Background and Aims Among patients with cirrhosis awaiting liver transplantation, prediction of wait‐list (WL) mortality is adjudicated by the Model for End Stage Liver Disease–Sodium (MELD‐Na) score. Replacing serum creatinine (SCr) estimated glomerular filtration rate (eGFR) in MELD‐Na score may improve WL mortality, especially women highest disease severity. Approach Results We developed (2014) validated (2015) a model incorporating eGFR using national data (n = 17,095) to predict...
Compared to other chronic diseases, patients with liver disease (CLD) have significantly higher inpatient mortality; accurate models predict mortality are lacking. Serum lactate (LA) may be elevated in CLD due both tissue hypoperfusion as well decreased LA clearance. We hypothesized that a parsimonious model consisting of Model for End-Stage Liver Disease (MELD) and at admission CLD.We examined all two large diverse health care systems Texas (North [NTX] Central [CTX]) between 2010 2015....
Interferon (IFN)‐free regimens are needed to treat hepatitis C virus (HCV) infection. Combined simeprevir (SMV) and sofosbuvir (SOF) with or without ribavirin (RBV) results in high sustained virological response (SVR) rates along minimal adverse events (AEs) patients genotype 1 (HCV GT1). The aim of this study was report on the response, safety, tolerability SOF SMV RBV compensated decompensated cirrhosis HCV GT1 Patients treated standardized clinical protocol utilizing SMV+SOF at three...
Simultaneous liver kidney (SLK) transplants reverse end-stage disease (ESLD) and renal (ESRD) at one operation; Kidney after transplantation (KAL) via the safety net offers transplant priority to recipients who do not recover function following transplantation.We conducted a retrospective cohort study evaluating all SLK KAL from January 2018 December 2023 three geographically distinct programs.38 patients underwent KAL; 251 individuals were recipients.KAL predominantly female (64.3%) whereas...
Hyponatremia is associated with an increased risk of mortality on the liver transplantation (LT) waiting list. Although incorporation serum sodium (Na) level into Model for End-Stage Liver Disease score may reduce wait-list mortality, concerns remain about a potential association between pre-LT hyponatremia and decreased post-LT survival. Furthermore, relationship hypernatremia survival remains unexplored. The purpose this study was to investigate impact entire spectrum Na levels outcomes....
In the United States, 5% of adult liver transplant recipients receive a graft donation after circulatory determination death (DCDD). Concerns for ischemic cholangiopathy (IC), disease diffuse intrahepatic stricturing limits broader DCDD use. Single-center reports demonstrate large variation in outcomes.Retrospective deidentified data collected between 2005 and 2013 were entered electronically by 10 centers via Research Electronic Data Capture database. Our primary outcome was development...